Background. This study is aimed at constructing a nomogram to predict the risk of clinically significant prostate cancer (csPCa) based on the aggregate index of systemic inflammation (AISI) and prostate imaging‐reporting and data system version (PIRADS) score. Methods. Clinical data on patients who had undergone initial prostate biopsy from January 2019 to December 2021 were collected. Patients were randomized in a 7 : 3 ratio to the training cohort and the validation cohort. Potential risk factors for csPCa were identified by univariable and multivariate logistic regression. Nomogram was conducted with these independent risk factors, and calibration curves, the receiver operating characteristic (ROC), and decision curve analysis (DCA) were employed to assess the nomogram’s ability for prediction. Results. A total of 1219 patients were enrolled in this study. Multivariate logistic regression identified that age, AISI, total prostatic specific‐antigen (tPSA), free to total PSA (f/tPSA), prostate volume (PV), and PIRADS score were potential risk predictors of csPCa, and the nomogram was developed based on these factors. The area under the curve (AUC) of the training cohort and validation cohort was 0.884 (95% CI: 0.862‐0.906) and 0.899 (95% CI: 0.867‐0.931). The calibration curves showed that the apparent curves were closer to the ideal curves. The DCA results revealed that the nomogram model seemed to have clinical application value per DCA. Conclusion. The nomogram model can efficiently predict the risk of csPCa and may assist clinicians in determining if a prostate biopsy is necessary.
BACKGROUND Prostate cancer (PCa) is a widespread malignancy, predominantly affecting elderly males, and current methods for diagnosis and treatment of this disease continue to fall short. The marker Ki-67 (MKI67) has been previously demonstrated to correlate with the proliferation and metastasis of various cancer cells, including those of PCa. Hence, verifying the association between MKI67 and the diagnosis and prognosis of PCa, using bioinformatics databases and clinical data analysis, carries significant clinical implications. AIM To explore the diagnostic and prognostic efficacy of antigens identified by MKI67 expression in PCa. METHODS For cohort 1, the efficacy of MKI67 diagnosis was evaluated using data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. For cohort 2, the diagnostic and prognostic power of MKI67 expression was further validated using data from 271 patients with clinical PCa. RESULTS In cohort 1, MKI67 expression was correlated with prostate-specific antigen (PSA), Gleason Score, T stage, and N stage. The receiver operating characteristic (ROC) curve showed a strong diagnostic ability, and the Kaplan-Meier method demonstrated that MKI67 expression was negatively associated with the progression-free interval (PFI). The time-ROC curve displayed a weak prognostic capability for MKI67 expression in PCa. In cohort 2, MKI67 expression was significantly related to the Gleason Score, T stage, and N stage; however, it was negatively associated with the PFI. The time-ROC curve revealed the stronger prognostic capability of MKI67 in patients with PCa. Multivariate COX regression analysis was performed to select risk factors, including PSA level, N stage, and MKI67 expression. A nomogram was established to predict the 3-year PFI. CONCLUSION MKI67 expression was positively associated with the Gleason Score, T stage, and N stage and showed a strong diagnostic and prognostic ability in PCa.
Background: Non-obstructive azoospermia (NOA) is a prevalent cause of male infertility, characterized by the lack of sperm in the ejaculate due to impaired spermatogenesis. Accurate prediction of testicular sperm extraction (TESE) outcomes is pivotal for counseling and managing patients, yet remains challenging due to variability in clinical presentations. This study aimed to establish a predictive model for TESE outcomes in patients with NOA. Methods: We retrospectively analyzed 425 patients who visited the Andrology Outpatient Clinic of the First Affiliated Hospital of Soochow University between January 2010 and January 2024. Of these, 216 had positive sperm retrieval, and 209 had negative outcomes. We compared testicular volume, reproductive hormone levels, and other clinical parameters between two groups. Multivariate logistic regression was used to identify independent risk factors that were used to establish a predictive nomogram. A calibration curve was used to evaluate the model’s fit, whereas receiver operating characteristic (ROC) curves and decision curve analysis (DCA) were used to assess diagnostic effectiveness and net benefit. Results: The differences were significant in serum follicle-stimulating hormone (FSH) (P<0.001), body mass index (P=0.04), elastase levels (P=0.005), and testicular microlithiasis levels (P=0.005) between the groups. Multivariate regression identified FSH (P<0.001), testicular volume (P<0.001), and testosterone levels (P=0.003) as independent risk factors for TESE outcomes. FSH levels were negatively correlated [odds ratio (OR) =0.905, 95% confidence interval (CI): 0.876–0.935, P<0.001], while testicular volume (OR =1.453, 95% CI: 1.328–1.591, P<0.001) and testosterone (OR =1.326, 95% CI: 1.098–1.601, P=0.003) were positively correlated. Nomogram based on these factors showed a good fit with an area under the ROC curve of 0.879. The DCA plot demonstrated substantial clinical benefits. Conclusions: In patients with NOA, low testicular volume, low testosterone levels, and high FSH levels were independent risk factors for unsuccessful TESE. The predictive nomogram provided excellent predictive power for positive TESE outcomes.
Introduction: This study aimed to develop a preoperative predictive model for pathological grading of bladder urothelial carcinoma by integrating multi-parameter, thin-slice enhanced computed tomography (CT) texture features with relevant clinical indicators.Methods: CT images and clinical data were retrospectively collected from 372 individuals diagnosed with bladder urothelial carcinoma at our institution between January 2015 and October 2020. The cohort was categorized into high-grade urothelial carcinoma (HGUC; n = 190) and low-grade urothelial carcinoma (LGUC; n = 182). Participants were randomly assigned to a training group (n = 259) and a validation group (n = 113) in a 7:3 ratio. Regions of interest (ROIs) were delineated on all enhanced CT images using 3D-Slicer software, and 1,223 texture features encompassing first-order, second-order, high-order, and filtered attributes were extracted. Features with an intraclass correlation coefficient (ICC) above 0.75 were retained for further analysis via least absolute shrinkage and selection operator (LASSO) regression. A logistic regression model was constructed based on the selected features to develop a clinical prediction tool. The model’s performance was evaluated using the concordance index (C-index), calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA).Results: Eleven radiomics features demonstrated significant associations with the pathological grade of bladder urothelial carcinoma. Among the models evaluated, the logistic regression model exhibited the highest discriminative power, with an area under the curve (AUC) of 0.858. Multivariate analysis identified age and proteinuria as independent predictors. The integrated model, incorporating both clinical and imaging features, outperformed models based on clinical or radiomic data alone (AUC = 0.864).Conclusion: This study presents the first CT-based nomogram that integrates multiparametric radiomic features with comprehensive clinical indicators to preoperatively predict pathological grade in bladder urothelial carcinoma. The model offers a robust, accurate, and non-invasive tool that can facilitate individualized treatment planning and enhance clinical decision-making.
Introduction: This study examined the efficacy and safety of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer (MIBC).Methods: This retrospective cohort study included patients diagnosed with MIBC at the First Affiliated Hospital of Soochow University between January 1, 2020, and December 31, 2023, assigned to either chemotherapy (gemcitabine with cisplatin) or combination (chemotherapy plus toripalimab or tislelizumab) groups based on the neoadjuvant treatment regimen. Key metrics, including pathological downstaging rate (PDR), pathological complete response rate (PCRR), and incidence and severity of adverse events (AEs), were compared between groups.Results: This study included 53 patients (mean age: 67.21 years). In the combination group, 14 patients (51.85%) achieved pathological complete remission (ypT0), and seven (25.93%) achieved partial remission (ypT1), resulting in a PDR and PCRR of 77.78 and 51.85%, respectively. In the chemotherapy group, six patients (23.08%) achieved complete remission, and five (19.23%) achieved partial remission, resulting in a PDR and PCRR of 42.31 and 23.08%, respectively. Differences between groups were statistically significant (p < 0.05). There were no significant differences in pathological downstaging or complete remission rates among subgroups in the combination group (p > 0.05). No serious allergic reactions or fatal AEs were detected in either group, with no grade 4 AEs. Grade 3 AE rates were 22.22 and 20.83% in the combination and chemotherapy groups, respectively, although non-significant (p > 0.05).Conclusion: Neoadjuvant chemotherapy combined with immunotherapy had enhanced efficacy and manageable safety in patients with MIBC, suggesting its potential for integration into clinical practice.